The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2023 | Is it feasible to use imaging modalities as an endpoint in myeloma clinical trials?
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses the possibility of using imaging modalities as an endpoint in myeloma clinical trials. Currently, imaging is systematically included in all prospective clinical trials, and Dr Zamagni comments on why it may not be feasible to tailor treatment exclusively on imaging alone. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
